For Investors
At Kazia, we believe that the best thing we can do for our investors is to deliver high-quality science that makes a substantial impact on the lives of patients.
Our Value Proposition for Investors
Kazia's pipeline assets are scientifically well-validated, and their early development has been performed to the highest possible standards of quality in large pharmaceutical companies.
The company has a track record of successful partnering, both inbound and outbound and has demonstrated the ability to realise value from its pipeline, even prior to product approval.
Kazia is a lean, agile business, in which broad clinical trial programs have been deployed with a very high level of cost efficiency, and which has shown a consistent ability to deliver on its objectives.
